historically the problem is that live attenuated virae do present the "wrong" sites ... so after one clinical study with babies some 30/40/50(?) years ago went terribly wrong (immunized arm with much severe rsv infection than usual) all development stopped for a long time. only with the biotech revolution we have the analytical capabilities to identify/model to target sites (though still with the usual failures of plasmid/vlp approaches) ...
... which is the other challenge: strength/persistence of immmune response as with any vaccine, see i believe nvax's "failed" maternal immunization program (supported by gates, but too weak response for what a commercial use would demand)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.